Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development.

Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, Backes C, Vogelmeier C, Diener C, Biertz F, Herr C, Jörres RA, Lenhof HP, Meese E, Bals R; COSYCONET Study Group.

Genomics Proteomics Bioinformatics. 2018 Jul 5. pii: S1672-0229(18)30138-4. doi: 10.1016/j.gpb.2018.06.001. [Epub ahead of print]

2.

Design and application of an MR reference phantom for multicentre lung imaging trials.

Triphan SMF, Biederer J, Burmester K, Fellhauer I, Vogelmeier CF, Jörres RA, Kauczor HU, Heußel CP, Wielpütz MO, Jobst BJ.

PLoS One. 2018 Jul 5;13(7):e0199148. doi: 10.1371/journal.pone.0199148. eCollection 2018.

3.

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach.

Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.

4.

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.

Kardos P, Mokros I, Sauer R, Vogelmeier CF.

Int J Chron Obstruct Pulmon Dis. 2018 May 3;13:1455-1468. doi: 10.2147/COPD.S159827. eCollection 2018.

5.

Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans.

Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jörres RA.

Chron Respir Dis. 2018 Jan 1:1479972318775423. doi: 10.1177/1479972318775423. [Epub ahead of print]

PMID:
29742906
6.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

7.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

8.

Pharmacological treatment of COPD: the devil is always in the detail.

Singh D, Barnes PJ, Stockley R, Lopez Valera MV, Vogelmeier C, Agusti A.

Eur Respir J. 2018 Apr 19;51(4). pii: 1800263. doi: 10.1183/13993003.00263-2018. Print 2018 Apr. No abstract available.

PMID:
29674480
9.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
10.

Blood eosinophils as a marker of eosinophilic exacerbations in COPD.

Greulich T, Vogelmeier CF.

Lancet Respir Med. 2018 May;6(5):e17. doi: 10.1016/S2213-2600(18)30095-X. Epub 2018 Apr 5. No abstract available.

PMID:
29627195
11.

A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.

Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H.

Respir Res. 2018 Apr 4;19(1):55. doi: 10.1186/s12931-018-0751-x.

12.

Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling.

Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, Waschki B, Kleibrink BE, Welte T, Bals R, Schulz H, Biertz F, Young D, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Apr;137:14-22. doi: 10.1016/j.rmed.2018.02.011. Epub 2018 Feb 19.

PMID:
29605197
13.

Exacerbations of COPD.

Viniol C, Vogelmeier CF.

Eur Respir Rev. 2018 Mar 14;27(147). pii: 170103. doi: 10.1183/16000617.0103-2017. Print 2018 Mar 31.

14.

[Guideline for the Diagnosis and Treatment of COPD Patients - Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology].

Vogelmeier C, Buhl R, Burghuber O, Criée CP, Ewig S, Godnic-Cvar J, Hartl S, Herth F, Kardos P, Kenn K, Nowak D, Rabe KF, Studnicka M, Watz H, Welte T, Windisch W, Worth H; unter Mitwirkung der folgenden wissenschaftlichen Fachgesellschaften: Deutsche Gesellschaft für Arbeitsmedizin und Umweltmedizin e.V. ; Deutsche Gesellschaft für Rehabilitationswissenschaften e.V.

Pneumologie. 2018 Apr;72(4):253-308. doi: 10.1055/s-0043-125031. Epub 2018 Mar 9. German.

PMID:
29523017
15.

Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD.

Graf J, Lucke T, Herrera R, Watz H, Holle R, Vogelmeier C, Ficker JH, Jörres RA.

Pulm Pharmacol Ther. 2018 Apr;49:123-129. doi: 10.1016/j.pupt.2018.01.011. Epub 2018 Feb 5.

PMID:
29421666
16.

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.

17.

Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.

Miravitlles M, Roche N, Cardoso J, Halpin D, Aisanov Z, Kankaanranta H, Kobližek V, Śliwiński P, Bjermer L, Tamm M, Blasi F, Vogelmeier CF.

Respir Res. 2018 Jan 18;19(1):11. doi: 10.1186/s12931-018-0715-1. Review.

18.

[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Buhl R, Bals R, Baur X, Berdel D, Criée CP, Gappa M, Gillissen A, Greulich T, Haidl P, Hamelmann E, Kardos P, Kenn K, Klimek L, Korn S, Lommatzsch M, Magnussen H, Nicolai T, Nowak D, Pfaar O, Rabe KF, Riedler J, Ritz T, Schultz K, Schuster A, Spindler T, Taube C, Taube K, Vogelmeier C, von Leupold A, Wantke F, Weise S, Wildhaber J, Worth H, Zacharasiewicz A.

Pneumologie. 2017 Dec;71(12):e2. doi: 10.1055/s-0044-100881. Epub 2018 Jan 15. German. No abstract available.

PMID:
29334688
19.

The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort.

Wacker ME, Kitzing K, Jörres RA, Leidl R, Schulz H, Karrasch S, Karch A, Koch A, Vogelmeier CF, Holle R.

Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017.

20.

Prevalence of comorbidities in COPD patients by disease severity in a German population.

Greulich T, Weist BJD, Koczulla AR, Janciauskiene S, Klemmer A, Lux W, Alter P, Vogelmeier CF.

Respir Med. 2017 Nov;132:132-138. doi: 10.1016/j.rmed.2017.10.007. Epub 2017 Oct 12.

PMID:
29229085
21.

[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Deutsche Gesellschaft für Arbeitsmedizin und Umweltmedizin e. V; Deutsche Gesellschaft für Rehabilitationswissenschaften e.V; und Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V.;, Buhl R, Bals R, Baur X, Berdel D, Criée CP, Gappa M, Gillissen A, Greulich T, Haidl P, Hamelmann E, Kardos P, Kenn K, Klimek L, Korn S, Lommatzsch M, Magnussen H, Nicolai T, Nowak D, Pfaar O, Rabe KF, Riedler J, Ritz T, Schultz K, Schuster A, Spindler T, Taube C, Taube K, Vogelmeier C, von Leupold A, Wantke F, Weise S, Wildhaber J, Worth H, Zacharasiewicz A.

Pneumologie. 2017 Dec;71(12):849-919. doi: 10.1055/s-0043-119504. Epub 2017 Dec 7. German. Erratum in: Pneumologie. 2017 Dec;71(12 ):e2. Taube, R C [corrected to Taube, C].

22.

Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.

Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, Bals R, Fähndrich S.

Respir Med. 2017 Sep;130:1-8. doi: 10.1016/j.rmed.2017.07.004. Epub 2017 Jul 8.

PMID:
29206626
23.

European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency.

Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, McElvaney NG, Parr D, Piitulainen E, Roche N, Stolk J, Thabut G, Turner A, Vogelmeier C, Stockley RA.

Eur Respir J. 2017 Nov 30;50(5). pii: 1700610. doi: 10.1183/13993003.00610-2017. Print 2017 Nov. Review.

PMID:
29191952
24.

Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):968-969. doi: 10.1164/rccm.201710-2027LE. No abstract available.

PMID:
29140725
25.

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR.

Am J Respir Crit Care Med. 2018 May 1;197(9):1223-1226. doi: 10.1164/rccm.201709-1822LE. No abstract available.

PMID:
29099609
26.

Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD.

Zhumagaliyeva A, Ottaviani S, Greulich T, Gorrini M, Vogelmeier C, Karazhanova L, Nurgazina G, DeSilvestri A, Kotke V, Barzon V, Zorzetto M, Corsico A, Ferrarotti I.

Multidiscip Respir Med. 2017 Oct 25;12:23. doi: 10.1186/s40248-017-0104-5. eCollection 2017.

27.

Obstructive sleep apnea patients can be identified by ion mobility spectrometry-derived smell prints of different biological materials.

Greulich T, Fischer H, Lubbe D, Nell C, Ingo Baumbach J, Koehler U, Boeselt T, Vogelmeier C, Rembert Koczulla A.

J Breath Res. 2018 Feb 6;12(2):026006. doi: 10.1088/1752-7163/aa96e2.

PMID:
29083318
28.

Precision medicine in airway diseases: moving to clinical practice.

Agustí A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, Louis R, McDonald VM, Sterk PJ, Thomas M, Vogelmeier C, Pavord ID; on behalf of all participants in the seminar.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701655. doi: 10.1183/13993003.01655-2017. Print 2017 Oct.

PMID:
29051276
29.

GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.

Worth H, Buhl R, Criée CP, Kardos P, Lossi NS, Vogelmeier CF.

Respir Med. 2017 Oct;131:77-84. doi: 10.1016/j.rmed.2017.08.008. Epub 2017 Aug 9.

30.

[Chronic airway infections or colonization by problem pathogens?]

Salzberger B, Vogelmeier C, Welte T.

Internist (Berl). 2017 Nov;58(11):1125-1126. doi: 10.1007/s00108-017-0333-x. German. No abstract available.

PMID:
28929181
31.

Cardiovascular risk in patients with alpha-1-antitrypsin deficiency.

Fähndrich S, Biertz F, Karch A, Kleibrink B, Koch A, Teschler H, Welte T, Kauczor HU, Janciauskiene S, Jörres RA, Greulich T, Vogelmeier CF, Bals R; COSYCONET investigators.

Respir Res. 2017 Sep 15;18(1):171. doi: 10.1186/s12931-017-0655-1.

32.

Perception of symptoms and quality of life - comparison of patients' and physicians' views in the COPD MIRROR study.

Celli B, Blasi F, Gaga M, Singh D, Vogelmeier C, Pegoraro V, Caputo N, Agusti A.

Int J Chron Obstruct Pulmon Dis. 2017 Jul 27;12:2189-2196. doi: 10.2147/COPD.S136711. eCollection 2017.

33.

Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency.

Fähndrich S, Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, Bals R.

Respir Med. 2017 Aug;129:8-15. doi: 10.1016/j.rmed.2017.05.011. Epub 2017 May 24.

PMID:
28732839
34.

Blood eosinophil count and exacerbation risk in patients with COPD.

Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agustí A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E, Popov T, Roche N, Ryan D, Thomas M, Vogelmeier C, Chisholm A, Freeman D, Bafadhel M, Hillyer EV, Price DB.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700761. doi: 10.1183/13993003.00761-2017. Print 2017 Jul. No abstract available.

PMID:
28729477
35.

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators.

Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.

36.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time.

Rodriguez-Roisin R, Rabe KF, Vestbo J, Vogelmeier C, Agustí A; all previous and current members of the Science Committee and the Board of Directors of GOLD (goldcopd.org/committees/).

Eur Respir J. 2017 Jul 5;50(1). pii: 1700671. doi: 10.1183/13993003.00671-2017. Print 2017 Jul. No abstract available.

PMID:
28679615
37.

Erratum to "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary" [Arch Bronconeumol. 2017;53:128-49].

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Jul;53(7):411-412. doi: 10.1016/j.arbres.2017.06.001. English, Spanish. No abstract available.

38.

Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1230-1231. doi: 10.1164/rccm.201706-1105LE. No abstract available.

PMID:
28650724
39.

[Orphan diseases - on the way to better patient care].

Vogelmeier CF.

Dtsch Med Wochenschr. 2017 Jun;142(11):777-778. doi: 10.1055/s-0043-100842. Epub 2017 May 31. German. No abstract available.

PMID:
28564726
40.

Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.

Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, Bals R, Fähndrich S.

Int J Chron Obstruct Pulmon Dis. 2017 May 12;12:1427-1437. doi: 10.2147/COPD.S130925. eCollection 2017.

41.

Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort.

Kahnert K, Lucke T, Huber RM, Behr J, Biertz F, Vogt A, Watz H, Alter P, Fähndrich S, Bals R, Holle R, Karrasch S, Söhler S, Wacker M, Ficker JH, Parhofer KG, Vogelmeier C, Jörres RA; COSYCONET consortium.

PLoS One. 2017 May 15;12(5):e0177501. doi: 10.1371/journal.pone.0177501. eCollection 2017.

42.

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.

Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.

Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017.

43.

[Alpha-2 Macroglobulin Serum Level in Patients with Alpha-1 Antitrypsin Deficiency].

Kotke V, Wiedmann S, Nell C, Vogelmeier C, Bals R, Greulich T, Klemmer A.

Pneumologie. 2017 Sep;71(9):580-586. doi: 10.1055/s-0043-103137. Epub 2017 Apr 27. German.

PMID:
28449136
44.

Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients.

Karl FM, Holle R, Bals R, Greulich T, Jörres RA, Karch A, Koch A, Karrasch S, Leidl R, Schulz H, Vogelmeier C, Wacker ME; COSYCONET Study Group.

Respir Res. 2017 Apr 17;18(1):60. doi: 10.1186/s12931-017-0543-8.

45.

Benefits of High-Intensity Exercise Training to Patients with Chronic Obstructive Pulmonary Disease: A Controlled Study.

Boeselt T, Nell C, Lütteken L, Kehr K, Koepke J, Apelt S, Veith M, Beutel B, Spielmanns M, Greulich T, Vogelmeier CF, Kenn K, Janciauskiene S, Alter P, Koczulla AR.

Respiration. 2017;93(5):301-310. doi: 10.1159/000464139. Epub 2017 Mar 23.

46.

Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.

Calverley PMA, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EFM, Mezzanotte W, Disse B, Finnigan H, Asijee G, Hallmann C, Watz H.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1219-1221. doi: 10.1164/rccm.201612-2525LE. No abstract available.

PMID:
28306321
47.

A two-year evaluation of the 'real life' impact of COPD on patients in Germany: The DACCORD observational study.

Kardos P, Vogelmeier C, Worth H, Buhl R, Lossi NS, Mailänder C, Criée CP.

Respir Med. 2017 Mar;124:57-64. doi: 10.1016/j.rmed.2017.02.007. Epub 2017 Feb 16.

48.

Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 May 1;195(9):1189-1197. doi: 10.1164/rccm.201701-0193OC.

49.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Mar;53(3):128-149. doi: 10.1016/j.arbres.2017.02.001. Epub 2017 Mar 6. English, Spanish. Erratum in: Arch Bronconeumol. 2017 Jul;53(7):411-412.

50.

Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).

Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, Chavannes NH, de Sousa JC, Cruz AA, Haahtela T, Joos G, Khaltaev N, Malva J, Muraro A, Nogues M, Palkonen S, Pedersen S, Robalo-Cordeiro C, Samolinski B, Strandberg T, Valiulis A, Yorgancioglu A, Zuberbier T, Bedbrook A, Aberer W, Adachi M, Agusti A, Akdis CA, Akdis M, Ankri J, Alonso A, Annesi-Maesano I, Ansotegui IJ, Anto JM, Arnavielhe S, Arshad H, Bai C, Baiardini I, Bachert C, Baigenzhin AK, Barbara C, Bateman ED, Beghé B, Kheder AB, Bennoor KS, Benson M, Bergmann KC, Bieber T, Bindslev-Jensen C, Bjermer L, Blain H, Blasi F, Boner AL, Bonini M, Bonini S, Bosnic-Anticevitch S, Boulet LP, Bourret R, Bousquet PJ, Braido F, Briggs AH, Brightling CE, Brozek J, Buhl R, Burney PG, Bush A, Caballero-Fonseca F, Caimmi D, Calderon MA, Calverley PM, Camargos PAM, Canonica GW, Camuzat T, Carlsen KH, Carr W, Carriazo A, Casale T, Cepeda Sarabia AM, Chatzi L, Chen YZ, Chiron R, Chkhartishvili E, Chuchalin AG, Chung KF, Ciprandi G, Cirule I, Cox L, Costa DJ, Custovic A, Dahl R, Dahlen SE, Darsow U, De Carlo G, De Blay F, Dedeu T, Deleanu D, De Manuel Keenoy E, Demoly P, Denburg JA, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dray G, Dubakiene R, Durham SR, Dykewicz MS, El-Gamal Y, Emuzyte R, Fabbri LM, Fletcher M, Fiocchi A, Fink Wagner A, Fonseca J, Fokkens WJ, Forastiere F, Frith P, Gaga M, Gamkrelidze A, Garces J, Garcia-Aymerich J, Gemicioğlu B, Gereda JE, González Diaz S, Gotua M, Grisle I, Grouse L, Gutter Z, Guzmán MA, Heaney LG, Hellquist-Dahl B, Henderson D, Hendry A, Heinrich J, Heve D, Horak F, Hourihane JOB, Howarth P, Humbert M, Hyland ME, Illario M, Ivancevich JC, Jardim JR, Jares EJ, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Julge K, Jung KS, Just J, Kaidashev I, Khaitov MR, Kalayci O, Kalyoncu AF, Keil T, Keith PK, Klimek L, Koffi N'Goran B, Kolek V, Koppelman GH, Kowalski ML, Kull I, Kuna P, Kvedariene V, Lambrecht B, Lau S, Larenas-Linnemann D, Laune D, Le LTT, Lieberman P, Lipworth B, Li J, Lodrup Carlsen K, Louis R, MacNee W, Magard Y, Magnan A, Mahboub B, Mair A, Majer I, Makela MJ, Manning P, Mara S, Marshall GD, Masjedi MR, Matignon P, Maurer M, Mavale-Manuel S, Melén E, Melo-Gomes E, Meltzer EO, Menzies-Gow A, Merk H, Michel JP, Miculinic N, Mihaltan F, Milenkovic B, Mohammad GMY, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Morgan M, Mösges R, Mullol J, Nafti S, Namazova-Baranova L, Naclerio R, Neou A, Neffen H, Nekam K, Niggemann B, Ninot G, Nyembue TD, O'Hehir RE, Ohta K, Okamoto Y, Okubo K, Ouedraogo S, Paggiaro P, Pali-Schöll I, Panzner P, Papadopoulos N, Papi A, Park HS, Passalacqua G, Pavord I, Pawankar R, Pengelly R, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Poethig D, Pohl W, Popov TA, Portejoie F, Potter P, Postma D, Price D, Rabe KF, Raciborski F, Radier Pontal F, Repka-Ramirez S, Reitamo S, Rennard S, Rodenas F, Roberts J, Roca J, Rodriguez Mañas L, Rolland C, Roman Rodriguez M, Romano A, Rosado-Pinto J, Rosario N, Rosenwasser L, Rottem M, Ryan D, Sanchez-Borges M, Scadding GK, Schunemann HJ, Serrano E, Schmid-Grendelmeier P, Schulz H, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Simons FER, Sisul JC, Skrindo I, Smit HA, Solé D, Sooronbaev T, Spranger O, Stelmach R, Sterk PJ, Sunyer J, Thijs C, To T, Todo-Bom A, Triggiani M, Valenta R, Valero AL, Valia E, Valovirta E, Van Ganse E, van Hage M, Vandenplas O, Vasankari T, Vellas B, Vestbo J, Vezzani G, Vichyanond P, Viegi G, Vogelmeier C, Vontetsianos T, Wagenmann M, Wallaert B, Walker S, Wang DY, Wahn U, Wickman M, Williams DM, Williams S, Wright J, Yawn BP, Yiallouros PK, Yusuf OM, Zaidi A, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M, Mercier J.

Clin Transl Allergy. 2017 Feb 20;7:5. doi: 10.1186/s13601-016-0135-6. eCollection 2017.

Supplemental Content

Loading ...
Support Center